Table 5. Use and effect of short acting β-agonist trials in children aged 2–59 months presenting with respiratory symptoms in low-, middle-, and high-income, primary care settings.

	Greece, n = 72	Kyrgyzstan, n = 239	Vietnam, n = 239	Ugandaa, n = 221	Total, N = 771
SABA trial performed, n (%)	28 (38.9)	-	30 (12.6)	4 (1.8)	62 (8.0)
Positive response to SABA trial, n (%)	18 (64.3)	-	10 (33.3)	1 (25.9)	29 (46.8)

SABA: Short acting β-agonist

^a: In Uganda, the majority of clinics only had oral SABAs available.